Medullary Thyroid Carcinoma Surgical Cytoreduction Induces an Increase in Serum Calcitonin and Carcinoembryonic Antigen Doubling Times

Abstract

Serum calcitonin (Ct) and carcinoembryonic antigen (CEA) doubling times (DT) are considered to be strong prognostic markers in patients with medullary thyroid carcinoma (MTC). The Objective of this work is to study the effect of MTC debulking on Ct and CEA DTs. 4 patients with MTC are presented who after an initial neck operation had residual disease were followed-up with serial measurements of serum Ct and CEA for several years before and after a secondary incomplete removal of involved cervical lymph nodes.

The patients received no other treatment for MTC. Ct and CEA DTs were determined after fitting the Ct or CEA values to an exponential growth equation.

In patient A, Ct DT increased from 1.45 years (1.17–1.89, 95% CI) preoperatively, to 5.72 (3.22–25.77) postoperatively. In patient B, Ct DT was 1.63 years (1.36–2.02) preoperatively, and very long (serum Ct practically ceased increasing) postoperatively. In patient C, Ct DT was 4.03 years (2.22–21.58) before, and very long after the operation. In patient D, Ct DT from 1.16 years (0.82–1.99) before, increased to 4.21 years (3.04–6.86) after the operation. The changes in CEA DTs were similar to those of Ct DTs in 2 patients in whom the tumor was apparently producing the protein.

In conclusion, surgical MTC cytoreduction in 4 patients caused an increase in the Ct and CEA DTs, and the patients could be reclassified in new Ct DT-based strata with better prognosis than before the operation. We hypothesize that such tumor burden reduction may slow the growth of any residual MTC and we discuss mechanisms that could be responsible for this phenomenon.

Key words

medullary thyroid carcinoma cytoreduction - calcitonin doubling times - CEA doubling times

• References

• 1 Barbet J, Campion L, Kraeber-Bodéré F et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 6077-6084
• 2 Chigurupati S, Kulkarni T, Thomas S et al. Calcitonin stimulates multiple stages of angiogenesis by directly acting on endothelial cells. Cancer Res 2005; 65: 8519-8529
• 3 Cohen R, Campos JM, Salaün C et al., and Groupe d’étude des tumeurs à calcitonine (GETC) . Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 919-922
• 4 Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004; 10: 942-949
• 5 Fleming JB, Lee JE, Bouvet M et al. Surgical strategy for the management of medullary thyroid carcinoma. Ann Surg 1999; 230: 697-707
• 6 Gawlik T, d’Amico A, Szpak-Ulczoc S et al. The prognostic value of tumor markers doubling times in medullary thyroid carcinoma-preliminary report. Thyroid Research 2010; 3: 10-15
• 7 Giraudet AL, Ghulzan AA, Aupérin A et al. Progression of medullary thyroid carcinoma : assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158: 239-246
• 8 Kloos RT, Eng C, Evans DB et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association THYROID 2009; 19: 565-612
• 9 Meijer JAA, le Cessie S, van den Hout WB et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-anlysis. Clin Endocrinol (Oxf) 2010; 72: 534-542
• 10 Miyauchi A, Onishi T, Morimoto S et al. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 1984; 199: 461-466
• 11 Müller S, Poehnert D, Müller JA et al. Regulatory T cells in peripheral blood, lymph node, and thyroid tissue in patients with medullary thyroid carcinoma. World J Surg 2010; 34: 1481-1487
• 12 Napoletano C, Bellati F, Landi R et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010; 14: 2748-2759
• 13 Pantazi H, Papapetrou PD. Calcitonin levels are similar in goitrous euthyroid patients with or without thyroid antibodies, as well as in hypothyroid patients. Eur J Endocrinol 1998; 138: 530-535
• 14 Schorge JO, McCann C, Del Carmen MG. Surgical debulking of ovarian cancer: what difference does it make?. Rev Obstet Gynecol 2010; 3: 111-117
• 15 Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-4772
• 16 Zhu W, Hai T, Cote GJ. Medullary thyroid carcinoma cell lines contain a self-renewing CD133⁺ population that is dependent on RET proto-oncogene activity. J Clin Endocrinol Metab 2010; 95: 439-444